GHENT, Belgium--(BUSINESS WIRE)--March 27, 2006--Ablynx, the pioneer in the discovery and development of Nanobodies(TM), a novel class of antibody-derived therapeutic proteins, has announced that Dr Edwin Moses has accepted the Board's offer to extend his role as Chairman to include that of Chief Executive Officer. Edwin has been non-Executive Chairman of Ablynx since November 2004. He takes over the CEO role from Mark Vaeck, Ph.D., who will continue to support the Company in a consultative capacity.
